PRX002/RG7935, an Anti–α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease

[Farooqji]

binding of peripheral α-synuclein and in dose-dependent increases of PRX002 in CSF and reached CSF concentrations that may be expected to engage extracellular aggregated α-synuclein in the brain. All tested dose levels of PRX002 had acceptable safety and tolerability profiles, supporting the design of an ongoing phase 2 clinical trial, PASADENA (NCT03100149).

jamanetwork.com/journals/ja...